Rezolute, Inc. — Form 10-Q Summary
Reporting period: Three months ended September 30, 2021, the company’s fiscal first quarter. The filing was signed November 12, 2021. Rezolute is a clinical-stage biopharmaceutical company developing therapies for metabolic diseases; it has not generated revenue.
Financial performance and position
| Metric | Quarter ended September 30, 2021 | Prior-year quarter |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $5.8 million | $2.3 million |
| General and administrative expense | $1.9 million | $1.3 million |
| Total operating expenses / operating loss | $7.6 million | $3.6 million |
| Net loss | $7.8 million | $3.6 million |
| Net loss per share, basic and diluted | $0.92 | $0.62 |
| Cash used in operating activities | $6.3 million | $3.6 million |
As of September 30, 2021, cash and cash equivalents were $37.3 million, working capital was approximately $35.7 million, and total assets were $38.8 million. Total liabilities were $17.2 million, including $14.1 million of net long-term debt; shareholders’ equity was $21.6 million. The filing reports no revenue or gross margin, so operating margins are not meaningful.
Changes versus the prior comparable period
- R&D expense increased 146% year over year, primarily from higher clinical-trial costs for RZ402 and RZ358 and increased R&D staffing.
- G&A expense increased 46%, largely due to professional, consulting, financial advisory and share-based compensation costs.
- Net loss more than doubled, reflecting higher operating expenses and $0.4 million of interest expense on the loan entered into in April 2021. The prior-year quarter had no comparable interest expense.
- Operating cash use increased by $2.8 million year over year. The company received $2.7 million from equity issuance during the quarter, and cash declined from $41.0 million at June 30 to $37.3 million at September 30.
Pipeline, outlook, and risks
- RZ358: In Phase 2b development for congenital hyperinsulinism. The RIZE trial had been paused in March 2020 due to COVID-19 and later resumed; management expected top-line results in the first quarter of calendar 2022, subject to pandemic conditions.
- RZ402: In Phase 1 development for diabetic macular edema. The multiple-ascending-dose study began in August 2021, with completion planned by the first quarter of calendar 2022. If results are favorable, management expected to advance toward a Phase 2a study in the second half of calendar 2022.
- Management estimated that September-end cash plus approximately $51.7 million of net proceeds from October offerings would fund currently planned activities into November 2022. The company expects continued operating losses and may need additional capital.
- The April 2021 loan provides a funded $15 million tranche and potential additional $7.5 million tranches, subject to financing and clinical milestones. The additional tranches were not assured; the company had met the financing threshold for term B but had not met the clinical milestones for term B or C. Term C also required an additional $12.3 million of financing. The loan is secured by substantially all company assets, including intellectual property, and includes a required $5 million minimum cash balance under specified conditions.
- In October 2021, the company completed an underwritten offering and a registered direct offering, generating approximately $51.7 million in combined net proceeds. The underwritten offering included common shares and pre-funded warrants, resulting in substantial potential dilution.
- COVID-19 could disrupt trial enrollment, clinical-site activity, supply and operations, and access to capital. Management said the quarter’s financial results were not significantly affected, but future impact remained uncertain.
- Management identified two material weaknesses in internal control over financial reporting as of June 30, 2021: inadequate segregation of duties due to limited staffing and ineffective treasury controls over authorized shares and share-issuance commitments. The share authorization deficiency was cured in May 2021; management said the weaknesses had not been fully remediated.
- No material pending or threatened litigation was reported. The filing also discloses potential milestone payments under license agreements, including up to $37.0 million to Xoma and up to $46.5 million under the ActiveSite agreement, subject to specified events.
Important facts for investors to verify
- Whether RZ358 and RZ402 meet trial milestones and whether reported clinical timelines remain achievable.
- Actual cash burn and financing needs relative to management’s estimated runway into November 2022.
- Eligibility for, and any decision to draw, the conditional term B and term C loans, including their milestones, financing requirements and cash restrictions.
- The dilution and share-count effects of October’s common-stock and pre-funded-warrant offerings and any future equity sales.
- Progress in remediating the disclosed material weaknesses in internal controls.